Press Releases Search News Category Company ReleasesCompany StatementsFinancial ReleasesProduct Releases Year None202320222021202020192018201720162015201420132012201120102009200820072006 Date Title PDF Version Nov 29, 2023 AstraZeneca advances scientific leadership in hematology at ASH 2023 Sep 20, 2023 Alexion completes purchase and licence agreement for early-stage rare disease gene therapy portfolio from Pfizer Sep 06, 2023 Update on US regulatory review of ULTOMIRIS® in NMOSD Jul 28, 2023 Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies Jun 09, 2023 Danicopan as add-on to ULTOMIRIS® or SOLIRIS® improved hemoglobin levels and maintained disease control in patients with PNH experiencing signs or symptoms of clinically significant extravascular hemolysis Mar 02, 2023 Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023 Nov 30, 2022 AstraZeneca showcases strength of hematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022 Nov 16, 2022 Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics Oct 27, 2022 ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks Oct 12, 2022 Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 626